NCT03990519View on ClinicalTrials.gov

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

February 19, 2020

Study Completion Date

February 19, 2020

Conditions
Healthy
Interventions
DRUG

JNJ-26366821

Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).

DRUG

Placebo

Participants will receive sodium chloride injection as placebo on Day 1.

Trial Locations (1)

21225

Harbor Hospital, Baltimore

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03990519 - A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants | Biotech Hunter | Biotech Hunter